Stock A078160 MEDIPOST CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MEDIPOST Co., Ltd.

Equities

A078160

KR7078160009

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-06-23 EDT 		5-day change 1st Jan Change
6,460 KRW -0.31% Intraday chart for MEDIPOST Co., Ltd. -3.15% -20.83%
04-24 Medip MEDIPOST CDMO Co., Ltd. announced that it has received KRW 30 billion in funding from MEDIPOST Co., Ltd. CI
04-23 Medip MEDIPOST CDMO Co., Ltd. announced that it expects to receive KRW 30 billion in funding from MEDIPOST Co., Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 567,258 542,459 536,260 345,507 240,563 278,246
Enterprise Value (EV) 1 546,558 512,300 519,801 317,697 166,460 130,335
P/E ratio -283 x -38.4 x -283 x -498 x 78.4 x 35.3 x
Yield - - - - - -
Capitalization / Revenue 12.8 x 11.8 x 11 x 6.3 x 3.75 x 4.05 x
EV / Revenue 12.3 x 11.2 x 10.7 x 5.79 x 2.59 x 1.9 x
EV / EBITDA -282 x -160 x 195 x -385 x -13.8 x -6.72 x
EV / FCF -363 x 101 x -21.8 x -15.3 x 47.9 x -3.44 x
FCF Yield -0.28% 0.99% -4.58% -6.56% 2.09% -29.1%
Price to Book 4.47 x 4.86 x 4.6 x 2.17 x 1.34 x 0.89 x
Nbr of stocks (in thousands) 15,499 15,499 15,499 16,145 16,145 34,099
Reference price 2 36,600 35,000 34,600 21,400 14,900 8,160
Announcement Date 3/11/19 3/13/20 3/19/21 3/21/22 3/15/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 44,384 45,811 48,625 54,856 64,201 68,643
EBITDA 1 -1,938 -3,200 2,670 -826.1 -12,052 -19,392
EBIT 1 -6,593 -8,064 -2,433 -5,724 -17,434 -25,263
Operating Margin -14.85% -17.6% -5% -10.44% -27.15% -36.8%
Earnings before Tax (EBT) 1 -3,686 -8,011 307.2 602.4 6,508 4,414
Net income 1 -2,007 -14,120 -1,896 -683.3 3,069 5,840
Net margin -4.52% -30.82% -3.9% -1.25% 4.78% 8.51%
EPS 2 -129.5 -911.0 -122.3 -43.00 190.0 231.0
Free Cash Flow 1 -1,505 5,067 -23,825 -20,828 3,476 -37,893
FCF margin -3.39% 11.06% -49% -37.97% 5.41% -55.2%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - 113.29% -
Dividend per Share - - - - - -
Announcement Date 3/11/19 3/13/20 3/19/21 3/21/22 3/15/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 20,699 30,159 16,459 27,810 74,103 147,912
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1,505 5,067 -23,825 -20,828 3,476 -37,893
ROE (net income / shareholders' equity) -1.74% -11.8% -1.66% -0.69% 1.01% 1.63%
ROA (Net income/ Total Assets) -2.57% -2.59% -0.7% -1.51% -3.34% -3.73%
Assets 1 78,022 545,605 270,312 45,255 -91,795 -156,673
Book Value Per Share 2 8,182 7,200 7,520 9,878 11,147 9,137
Cash Flow per Share 2 408.0 768.0 599.0 668.0 920.0 1,100
Capex 1 1,293 9,309 7,850 10,175 3,227 2,560
Capex / Sales 2.91% 20.32% 16.14% 18.55% 5.03% 3.73%
Announcement Date 3/11/19 3/13/20 3/19/21 3/21/22 3/15/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MEDIPOST CO., LTD. Stock MEDIPOST Co., Ltd.
-20.83% 159M
MODERNA, INC. Stock Moderna, Inc.
+38.36% 52.5B
LONZA GROUP AG Stock Lonza Group AG
+36.73% 39.31B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.63% 39.01B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.46% 28.2B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.57B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.44% 26.2B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.09% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.93% 12.62B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.30% 11.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A078160 Stock
  4. Financials MEDIPOST Co., Ltd.